Melhem-Bertrandt A - Search Results

1

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.

Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Melhem-Bertrandt A, et al. Cancer. 2012 Feb 15;118(4):908-13. doi: 10.1002/cncr.26377. Epub 2011 Jul 14. Cancer. 2012. PMID: 21761402 Free PMC article.

2

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.

Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Bayraktar S, et al. Cancer. 2012 May 1;118(9):2385-93. doi: 10.1002/cncr.26555. Epub 2011 Sep 27. Cancer. 2012. PMID: 21953213 Free PMC article.

3

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes.

Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M. Chae YK, et al. J Cancer. 2013 Aug 10;4(7):549-56. doi: 10.7150/jca.6888. eCollection 2013. J Cancer. 2013. PMID: 23983819 Free PMC article.

4

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Murthy RK, et al. Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689. Epub 2014 Mar 26. Cancer. 2014. PMID: 24677057 Free article.

5

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Melhem-Bertrandt A, et al. J Clin Oncol. 2011 Jul 1;29(19):2645-52. doi: 10.1200/JCO.2010.33.4441. Epub 2011 May 31. J Clin Oncol. 2011. PMID: 21632501 Free PMC article.

6

Leptomeningeal disease and breast cancer: the importance of tumor subtype.

Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Abouharb S, et al. Among authors: melhem bertrandt a. Breast Cancer Res Treat. 2014 Aug;146(3):477-86. doi: 10.1007/s10549-014-3054-z. Epub 2014 Jul 20. Breast Cancer Res Treat. 2014. PMID: 25038877 Review.

7

National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer.

Lee RT, Barbo A, Lopez G, Melhem-Bertrandt A, Lin H, Olopade OI, Curlin FA. Lee RT, et al. Among authors: melhem bertrandt a. J Clin Oncol. 2014 Dec 20;32(36):4095-101. doi: 10.1200/JCO.2014.55.8676. Epub 2014 Nov 17. J Clin Oncol. 2014. PMID: 25403205 Free PMC article.

8

Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Chae YK, et al. J Clin Oncol. 2013 Aug 10;31(23):e398-400. doi: 10.1200/JCO.2012.46.6383. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796991 Free PMC article. No abstract available.

9

New directions in reducing stress effects on cancer.

Melhem-Bertrandt A, Sood AK. Melhem-Bertrandt A, et al. Cancer Prev Res (Phila). 2012 Feb;5(2):147-9. doi: 10.1158/1940-6207.CAPR-11-0579. Cancer Prev Res (Phila). 2012. PMID: 22307563

10

Adrenergic signaling and cancer: deciphering the connections.

Melhem-Bertrandt A, Sood AK. Melhem-Bertrandt A, et al. Cancer Biomark. 2013;13(3):131-2. doi: 10.3233/CBM-130333. Cancer Biomark. 2013. PMID: 23912484 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page